Core Focus

 

Mycology Development

istockphoto-1178534783-612x612.jpg

• On site secured growing facility
 

• Mycology expertise augmented by laboratory

agreements to analyze PsiloTec mushroom genetics
 

• Exclusively licensed IP to enhance yields and

speed of harvest
 

• Unique strains of mushrooms secured along

with ongoing research and development of

new IP protected strains
 

• Anticipated production of psilocybin for clinical trials

beginning Q2, 2021, at partnered sites
 

• Estimated production commencing in
Alberta in Q4, 2021

e-Clinic and

Trial Development

 
Image by Louis Reed

• Unique novel clinical trial approach to reduce both

cost and time required for studies
 

• Manage research trials with a focus on IP

achievable compounds and processes
 

• On site lab expertise and partnerships
with post secondary institutions

 

• Formulations to support the needs in the mental

health sector, including PTSD, depression

and addictions
 

• Focus on organic psilocybin and related compounds

for maximal clinical benefits and IP protection
 

• Phase 2 clinical studies begin in Q3, 2021.

 
istockphoto-1250536878-612x612.jpg

Business Development

• Organic psilocybin mushroom sales for

research studies
 

• Channel agreements with clinical treatment centres for unique, branded products
 

• Potential naturopathic mushroom line for

various end user products
 

• Direct to client through multiple IP protected

doses and product combinations
 

• IP acquisition of unique product delivery systems
 

• Unique monitoring tools and training program

allowing for remote clinical and therapy interactions

instead of traditional clinical setting